Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer
Purpose: Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been perfor...
Main Authors: | Amal Al Omari, Hadeel Abdelkhaleq, Maysa Al-Hussaini, Rim Turfa, Nour Awad, Manal M. Hassan, Mahmoud A. Alfaqih, Christopher R. Garrett |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2018-06-01
|
Series: | Journal of Global Oncology |
Online Access: | http://ascopubs.org/doi/10.1200/JGO.18.00018 |
Similar Items
-
Frequency of Mismatch Repair Protein (MMRP) Deficiency among Young Jordanians Diagnosed with Colorectal Carcinoma (CRC)
by: Bayan Maraqa, et al.
Published: (2020-01-01) -
Metformin Treatment for Diabetes Mellitus Correlates with Progression and Survival in Colorectal Carcinoma
by: Marta K. Powell, et al.
Published: (2020-02-01) -
Metformin and Colorectal Cancer
by: Takuma Higurashi, et al.
Published: (2018-10-01) -
Metformin use and the incidence of colorectal and lung cancer in patients with type 2 diabetes mellitus
by: Smiechowski, Brielan
Published: (2012) -
Stem Cell Statute in Jordan: Leading the Way
by: Amal Al-Tabba’, et al.
Published: (2020-07-01)